Zanidatamab zovodotin (ZW49) consists of an anti-HER2 biparatopic IgG1 antibody (ZW25, zanidatamab) conjugated to a microtubule inhibitor auristatin payload (ZD02044) via a protease cleavable linker at a DAR of 2. Figure 4.

Jan 27, 2021 · ZW49, Zymeworks’ second product candidate, is a novel bispecific HER2-targeted ADC developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 combines the unique design of zanidatamab with a proprietary cytotoxin and cleavable linker resulting in enhanced internalization and tumor cell killing.

Jan 12, 2023 · proprietary ZymeLink Auristatin to the Azymetric anti -HER2 IgG1, ZW25, via a protease cleavable linker. The Azymetric biparatopic antibody of ZW49 demonstrates lysosomal trafficking and superior internalization relative to a HER2 -targeted monospecific ADC. The unique properties of the ZymeLink Auristatin of ZW49 enable greater tolerability and

Nov 8, 2023 · ZW49是用Azymetric和ZymeLink技术平台研发的双抗ADC，靶向ECD4和ECD2两个不同的HER2表位，通过可切割的二硫化物连接子偶联ZW25双抗和auristatin载荷。 目前处于HER2表达实体瘤的I期，此前公布的数据显示总ORR31%，治疗HER2+乳腺癌ORR为13%。 此外，ZW49在启动一项ZW49与 PD-1 抑制剂联合治疗局部晚期（不可切除）或转移性 HER2 表达非鳞状非小细胞肺癌（NSCLC）受试者的 2 期研究。 这项研究预计将在亚洲、北美和欧洲招募患 …

Feb 15, 2019 · ZW49 is an antibody drug conjugate (ADC) that combines a novel auristatin payload (potent anti-cancer agent) with the unique mechanisms of action of the anti-HER2 biparatopic antibody, ZW25, which binds to the same domains as trastuzumab and pertuzumab.

Jul 1, 2018 · Here we present the preclinical characterization of a new anti-HER2 biparatopic ADC, ZW49, which is generated from the conjugation of a novel N-acyl sulfonamide auristatin payload to the inter-chain disulfide bond cysteines of the bispecific anti-HER2 IgG1 antibody ZW25, via a protease cleavable linker.

anti-HER2 bispecific antibody-drug conjugate ZW49 An antibody-drug conjugate (ADC) consisting of a bispecific monoclonal antibody (ZW25) directed against two different epitopes of the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2, receptor tyrosine-protein kinase erbB-2) linked to an as of yet undisclosed ...

Oct 4, 2023 · • ZW49 2.5 mg/kg Q3W IV showed encouraging antitumor activity in heavily pretreated patients with advanced HER2+ cancers 30% cORR with a response duration range of 1.4 – 19.8* months • These data support further investigation of ZW49 2.5 mg/kg Q3W IV as a potential novel treatment option for advanced HER2+ cancers

Apr 4, 2023 · Zanidatamab zovodotin (ZW49) is an antibody drug conjugate (ADC) comprised of a bispecific anti-HER2 IgG1 antibody (ZW25, zanidatamab) conjugated to a microtubule inhibitor auristatin payload (ZD02044) via a protease cleavable linker.

Jan 4, 2023 · Zymeworks 公司有一款双抗Zanidatamab（ZW25）已经进入三期临床，表现优异，公司在ZW25的基础上布局了双抗ADC-Zanidatamab Zovodotin（ZW49）。 ZW-49的母体单抗是两款已上市的抗体，分别为trastuzumab（曲妥珠）和pertuzumab（帕妥珠），两个母单抗分别识别HER2受体的两个非重叠表位--ECD4和ECD2，通过二硫键偶联一种新颖的微管抑制剂。 图注：ZW49的结构设计. 在临床前PDX模型中，ZW49表现出对HER2低表达和高表达均表现出有 …